Risks of nimodipine dose reduction during the high-risk period for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

• Published in: Neurosurgical review 2024-01, Vol.47 (1), p.37-37, Article 37
• Main Authors: Ditz, Claudia, Matone, Maria V., Schwachenwald, Bram, Küchler, Jan
• Format: Article
• Language: English
• Subjects: Cerebral Infarction - drug therapy; Cerebral Infarction - etiology; Drug Tapering; Humans; Medicine; Medicine & Public Health; Neurosurgery; Nimodipine - therapeutic use; Retrospective Studies; Subarachnoid Hemorrhage - complications; Subarachnoid Hemorrhage - drug therapy; Subarachnoid Hemorrhage - surgery; Vasospasm, Intracranial - drug therapy; Vasospasm, Intracranial - etiology
• ISSN: 1437-2320; 1437-2320
• DOI: 10.1007/s10143-023-02273-0

Nimodipine dose reduction is recommended in case of high vasopressor demand after aneurysmal subarachnoid hemorrhage (aSAH). The aim of this study was to assess potential adverse effects of nimodipine reduction during the high-risk period for delayed cerebral ischemia (DCI) and cerebral vasospasm (CVS) between days 5 and 10 after hemorrhage. Demographic and clinical data as well as daily nimodipine dose of aSAH patients admitted between 2010 and 2019 were retrospectively analyzed. Univariable and multivariable regression analyses were performed to identify factors associated with DCI, angiographic CVS, DCI-related infarction, and unfavorable outcome. A total of 205 patients were included. Nimodipine dose reduction occurred in 108 (53%) patients (‘nimodipine reduction group’), while 97 patients (47%) received the full dose (‘no nimodipine reduction group’), Patients in the ‘nimodipine reduction group’ had significant worse WFNS and Fisher grades and developed significantly more often DCI and angiographic CVS. DCI-related infarction and unfavorable outcome were also significantly increased in the ‘nimodipine reduction group.’ ‘Reduced nimodipine dose’ was the only independent predictor for the occurrence of DCI and angiographic CVS in multivariable regression analysis. ‘Poor WFNS grade’ and ‘reduced nimodipine dose’ were identified as independent risk factors for DCI-related infarction while ‘older age,’ ‘poor WFNS grade,’ and ‘reduced nimodipine dose’ were associated with unfavorable outcome at 3 months after discharge. Nimodipine dose reduction during the high-risk period of DCI and CVS between days 5 and 10 after hemorrhage might abrogate the positive prognostic effects of nimodipine and should be critically evaluated.